<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611426</url>
  </required_header>
  <id_info>
    <org_study_id>ZGrhT001</org_study_id>
    <nct_id>NCT03611426</nct_id>
  </id_info>
  <brief_title>Topical rhThrombin as an Adjunct to Hemostasis During Segmental Hepatectomy</brief_title>
  <official_title>A Randomized，Ascending Dose，Single-blind Phase 1&amp;2 Study to Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of Topical rhThrombin as an Adjunct to Hemostasis During Segmental Hepatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      rhThrombin is a serine protease from human.The study is to assess the Safety, Tolerability,&#xD;
      Immunogenicity and efficacy of rhThrombin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, single-blind,blank controlled phase 1&amp;2 trial ,including 3&#xD;
      independent parts toevaluate the safety,efficacy and immunogenicity.&#xD;
&#xD;
      The first part is ascending dose,blank control tolerability and safety study. The Starting&#xD;
      doses from 500IU/ml to 1000IU/mL and 2000IU/mL to evaluate the safety,efficacy.&#xD;
&#xD;
      The second part is randomized, single-blind, blank controlled study to evaluate&#xD;
      safety、efficacy and immunogenicity. Doses settings :1000IU/mL , 2000IU/mL and blank group&#xD;
      which with absorbable collagen sponge when used.&#xD;
&#xD;
      The third part is randomized, single-blind, blank controlled study to evaluate&#xD;
      safety、efficacy and immunogenicity. Doses settings :1000IU/mL , 2000IU/mL and blank group&#xD;
      which directly sprayed on hemorrhagic point when used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Actual">July 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 5, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The first part is ascending dose study: 3 subjects take rhThromb and 1 subjects take the same volume of saline; The second part is dose extension study:2 cohorts and 1 blank control group( the same volume of saline) used with absorbable collagen sponge;every group need 12 subject; The second part is dose extension study: 2 cohorts and 1 blank control group( the same volume of saline);every group need 12 subject;</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of adverse events</measure>
    <time_frame>baseline to 4 weeks</time_frame>
    <description>Incidence and Severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving Hemostasis by Six Minutes After Treatment Start</measure>
    <time_frame>From start of treatment until 6 minutes after treatment start</time_frame>
    <description>Subjects achieving hemostasis at the target bleeding site by 6 minutes following the start of treatment without the occurrence of re-bleeding until the completion of surgical closure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The hemostatic time of the woud</measure>
    <time_frame>From start of treatment until 6 minutes after treatment start</time_frame>
    <description>The hemostatic time of the woud</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunogenicity</measure>
    <time_frame>baseline to 4 weeks</time_frame>
    <description>Incidence of rhThrombin antibody and Confirm whether they are neutralizing antibody</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Hepatectomy</condition>
  <arm_group>
    <arm_group_label>rhThrombin ( Topical )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1:rhThrombin ( Topical ) 500IU /ml、1000IU/m and 2000IU/ml During segmental hepatectomy; Cohort 2:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml with absorbable collagen sponge During segmental hepatectomy; Cohort 3:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml used directly sprayed on hemorrhagic point During segmental hepatectomy;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 1: the same volume of saline during segmental hepatectomy; Cohort 2:the same volume of saline used withabsorbable collagen sponge during segmental hepatectomy; Cohort 3:the same volume of saline during segmental hepatectomy;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhThrombin ( Topical )</intervention_name>
    <description>Active Substance</description>
    <arm_group_label>rhThrombin ( Topical )</arm_group_label>
    <other_name>Recombinant Human Thrombin (CHO Cell) for Topical Use</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>saline solution</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>PLA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects between 18 and 75 years of age;&#xD;
&#xD;
          2. Hepar wedge resection or anatomic hepatectomy(one to five continue hepatic segments)&#xD;
             (remark:including open surgery or hand-assisted laparoscopic surgery,patients who has&#xD;
             been cholecystectomy or choledochotomy can be also get into the study);&#xD;
&#xD;
          3. Blood routine(including WBC、ANC、RBC、Hb and PLT) and Liver&#xD;
             function(ALT≤1.5ULN、AST≤1.5ULN) is appear normal. ALP、LDH、 TBil、Dbil are&#xD;
             normal.(Remark: Patients whose Laboratory tests are abnormal but they are no clinical&#xD;
             significance can get into the study);&#xD;
&#xD;
          4. Renal function(including Cr、BUN)、coagulation function（including PT、APTT、TT、INR）、&#xD;
             electrolytes（include K、Na、CL、Ca、P、Mg）and electrocardiogram are normal or&#xD;
             anormal.Investigator think they make no difference to operation;&#xD;
&#xD;
          5. No other therapeutic surgery was performed in the first 4 weeks before the subject&#xD;
             gets into clinical research the study(in addition to diagnostic surgery).&#xD;
&#xD;
          6. Patients have not used blood products in 24hours before surgery.&#xD;
&#xD;
          7. Meet the requirements of the ethics committee.Sign the informed consent form and&#xD;
             visited according to the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Blood system diseases are known, including coagulopathy or bleeding tendency;&#xD;
&#xD;
          2. Life signs were not stable for more than 24hours;&#xD;
&#xD;
          3. Severe heart、brain and blood vessel diseases in past 6 months,including&#xD;
             TIA、Non-disabling cerebral infarction、myocardial infarction、unstable angina or&#xD;
             Intracranial hemorrhage;&#xD;
&#xD;
          4. Using the drugs that have an effect on blood coagulation in 7 days before&#xD;
             surgey(including but not limited to:&#xD;
             aspirin、clopidogrel、ticlopidine、dipyridamole、ginkgo biloba&#xD;
             extract、heparin、warfarin、citrates、hemocoagulase、VitK、ethamsylate and Vitc,etc);&#xD;
&#xD;
          5. Complicated with other serious diseases(active infections,uncontrolled diabetes and&#xD;
             hyperthyroidism);&#xD;
&#xD;
          6. Be allergic to thrombin(human)、serum(snake) and proteins (hamster);&#xD;
&#xD;
          7. Female subjects are in lactation or serum pregnancy test are positive;&#xD;
&#xD;
          8. Take part in other clinical trail within 4 weeks before geting into the study;&#xD;
&#xD;
          9. Using the Thrombin products and Antithrombin antibodies or Coagulation V factor&#xD;
             antibodies are positive before, after using rhthrombin, it may generate an immune&#xD;
             response.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiwei Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Medical School of Zhejiang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhiwei Li</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Serine protease</keyword>
  <keyword>Tolerance</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

